Research programme: DNA-based monoclonal antibodies - GeneOne Life Science

Drug Profile

Research programme: DNA-based monoclonal antibodies - GeneOne Life Science

Alternative Names: Anti-Aβ antibody; Anti-Her2 antibody; Anti-PD1 antibody

Latest Information Update: 04 Jun 2016

Price : $50

At a glance

  • Originator GeneOne Life Science
  • Developer Asan Medical Center; GeneOne Life Science; Kangwon National University; Yonsei University Health System
  • Class Antibodies; DNA
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cancer

Most Recent Events

  • 24 Feb 2016 GeneOne Life Science and Asan Medical Center agree to co-develop anti-Aβ antibody for Alzheimer's disease in South Korea (GeneOne Life Science pipeline, February 2016)
  • 24 Feb 2016 GeneOne Life Science, Kangwon National University and the Yonsei University agree to co-develop anti-Her2 and anti-PD1 antibodies for Cancer in South Korea (GeneOne Life Science pipeline, February 2016)
  • 24 Feb 2016 Preclinical trials in Alzheimer's disease in South Korea (Parenteral) (GeneOne Life Science pipeline, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top